title: Vasovagal syncope and skeletal muscle vasodilatation: the continuing conundrum.
abstract: During vasovagal syncope, profound bradycardia and hypotension occur. Atropine administration can prevent the bradycardia but not the hypotension, suggesting that marked peripheral vasodilation is a major cause of the fall in arterial pressure. This concept has been confirmed since vasovagal syncope can be seen in patients who have undergone heart transplantation and also in patients subject to cardiac pacing. In both cases, there is no bradycardia but hypotension during the syncopal attacks. The major site of the vasodilation is in skeletal muscle and muscle sympathetic nerve activity is suppressed just prior to and during vasovagal attacks, indicating that sympathetic withdrawal contributes to the dilation. However, the skeletal muscle vasodilation seen during syncope is greater than that caused by sympathetic withdrawal alone, and it is absent in limbs that have undergone surgical sympathectomy, or local anesthetic nerve block. These observations suggest a role for neurally mediated "active" vasodilation during syncope. The afferent neural pathways that evoke the profound vasodilation during vasovagal attacks remain the subject of debate. The neural pathways responsible for the active component of the dilation are also unknown. Recent evidence has demonstrated that cholinergic, beta-adrenergic, and nitroxidergic (nitric oxide) vasodilator mechanisms are not essential to observe the dilation, demonstrating that the mechanisms responsible for it remain a continuing conundrum.
authors.affiliation: Mayo Foundation, Rochester, Minnesota, USA.
authors.forename: N M
authors.initials: NM
authors.lastname: Dietz
authors.forename: M J
authors.initials: MJ
authors.lastname: Joyner
authors.forename: J T
authors.initials: JT
authors.lastname: Shepherd
mesh_terms: D000320:Adrenergic Fibers / Q000502:physiology; D000344:Afferent Pathways / Q000503:physiopathology; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D001919:Bradycardia / Q000150:complications / Q000517:prevention & control; D002304:Cardiac Pacing, Artificial; D002799:Cholinergic Fibers / Q000502:physiology; D016027:Heart Transplantation / Q000502:physiology; D006801:Humans; D007022:Hypotension / Q000150:complications; D018482:Muscle, Skeletal / Q000098:blood supply* / Q000294:innervation; D009407:Nerve Block; D009569:Nitric Oxide / Q000502:physiology; D013562:Sympathectomy; D013564:Sympathetic Nervous System / Q000503:physiopathology; D019462:Syncope, Vasovagal / Q000209:etiology / Q000503:physiopathology*; D014664:Vasodilation / Q000502:physiology*
chemical_list: D000889:Anti-Arrhythmia Agents; D009569:Nitric Oxide; D001285:Atropine